[go: up one dir, main page]

TR200002974T2 - Bruselloza karşı canlı aşı - Google Patents

Bruselloza karşı canlı aşı

Info

Publication number
TR200002974T2
TR200002974T2 TR2000/02974T TR200002974T TR200002974T2 TR 200002974 T2 TR200002974 T2 TR 200002974T2 TR 2000/02974 T TR2000/02974 T TR 2000/02974T TR 200002974 T TR200002974 T TR 200002974T TR 200002974 T2 TR200002974 T2 TR 200002974T2
Authority
TR
Turkey
Prior art keywords
vaccine against
live vaccine
against brucellosis
strain
brucella
Prior art date
Application number
TR2000/02974T
Other languages
English (en)
Inventor
P. Nikolich Mikeljon
L. Hoover David
L. Warren Richard
E. Lindler Luther
L. Hadfield Ted
G. Schurig Gerhardt
M. Boyle Stephen
R. Mcquiston John
Sriranganathan Nammalwar
Original Assignee
Walter Reed Army Institute Of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter Reed Army Institute Of Research filed Critical Walter Reed Army Institute Of Research
Publication of TR200002974T2 publication Critical patent/TR200002974T2/tr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Canli Brucella asilari ve bruselloza karsi koruyucu canli asilar hazirlamak için yöntemler açiklanmaktadir. Asilar, bir Brucella susunun rfbU genine, koruyucu bir immünojenik yaniti baslatmak için istenen immünojenisiteyi korurken susun zayiflatilmasiyla sonuçlanan bir delesyon dahil edilerek hazirlanir. Farkli zayiflatma seviyelerinde baska suslar da açiklanmaktadir.
TR2000/02974T 1998-01-22 1999-01-21 Bruselloza karşı canlı aşı TR200002974T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/010,877 US6444445B2 (en) 1998-01-22 1998-01-22 Live vaccine against Brucellosis

Publications (1)

Publication Number Publication Date
TR200002974T2 true TR200002974T2 (tr) 2001-01-22

Family

ID=21747840

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02974T TR200002974T2 (tr) 1998-01-22 1999-01-21 Bruselloza karşı canlı aşı

Country Status (5)

Country Link
US (1) US6444445B2 (tr)
AU (1) AU2462899A (tr)
IL (2) IL137449A0 (tr)
TR (1) TR200002974T2 (tr)
WO (1) WO1999037783A2 (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
US7416878B2 (en) * 2002-12-12 2008-08-26 The United States Of America As Represented By The Secretary Of The Army Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments
GB0307089D0 (en) * 2003-03-27 2003-04-30 Secr Defence Live vaccine strain
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
US20050249755A1 (en) * 2004-03-03 2005-11-10 Mikeljon Nikolich Mutant strains of Brucella melitensis and immunogenic compositions
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8778655B2 (en) * 2009-09-21 2014-07-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Modified gram-negative bacteria for use as vaccines
US9248176B2 (en) * 2010-10-07 2016-02-02 The Texas A&M University System Controlled release vaccines and methods for treating Brucella diseases and disorders
WO2013091040A2 (pt) * 2011-12-22 2013-06-27 Universidade Federal De Minas Gerais - Ufmg Cepa atenuada de brucella ovis, composição vacinal e uso
CN103864928A (zh) * 2012-12-13 2014-06-18 中国农业科学院哈尔滨兽医研究所 布鲁氏菌脂多糖共同抗原单克隆抗体的制备及c-ELISA方法的建立
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines

Also Published As

Publication number Publication date
WO1999037783A2 (en) 1999-07-29
AU2462899A (en) 1999-08-09
WO1999037783A9 (en) 1999-10-14
IL137449A0 (en) 2001-07-24
US6444445B2 (en) 2002-09-03
IL137449A (en) 2007-06-17
US20010014673A1 (en) 2001-08-16
WO1999037783A3 (en) 2000-02-03

Similar Documents

Publication Publication Date Title
TR200002974T2 (tr) Bruselloza karşı canlı aşı
ATE219948T1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
WO1999002186A3 (en) Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant
WO2022032196A3 (en) Multiepitope vaccine cassettes
BR9306707A (pt) Mutantes de deleção como vacinas contra cólera
WO1998017805A3 (en) Invasion associated genes from neisseria meningitidis serogroup b
CA2033640A1 (en) Vaccines against cancer and infectious diseases
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
WO1980002504A1 (en) Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
AR027680A1 (es) Vacuna contra la salmonella materiales y metodos
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
ES8207429A1 (es) Un procedimiento para la preparacion de un polisacarido antigenico.
DE69836520D1 (de) Clostridium perfringens Impfstoff
BR9707785A (pt) Parapoxvírus que contém dna estrangeiro preparação dos mesmos e uso dos mesmos em vacinas
WO2003070164A3 (en) Attenuated mycobacterium tuberculosis vaccines
DK1272652T3 (da) Herpesvirus til immunmodulation
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
AU5744800A (en) Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
CA2378862A1 (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
CA2366316A1 (en) Multi-component vaccine comprising at least three antigens to protect against disease caused by haemophilus influenzae
Chang Vaccination of mice with formalin-killed amastigotes of Leishmania mexicana against Leishmania donovani: Muramyl dipeptide-enhanced protection